drugset / Trial / NCT05517603
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of AJ201 In Patients
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a phase 1/2a randomized, double-blind study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of study drug AJ201 in subjects with Spinal and Bulbar Muscular Atrophy (SBMA).
Timeline
- Start
- 2023-02-28
- Primary completion
- 2024-04-08
- Completion
- 2024-04-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | AJ201 | Unknown | 600 mg | Oral |